SOHO 2023 | The future of MPN treatment: moving towards combination therapies
John Mascarenhas
• 9 Sep 2023
John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, comments on the direction of research in myeloproliferative neoplasms (MPNs), particularly the interest in combination approaches with JAK inhibitors. Dr Mascarenhas highlights the success of pelabresib, which is being investigated in combination with ruxolitinib for myelofibrosis (MF) in the MANIFEST-2 study (NCT04603495). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
